{
    "symbol": "BTCY",
    "quarter": 1,
    "year": 2022,
    "date": "2021-08-17 21:15:09",
    "content": " And I think that investors should be quite content with the fact that now that we have built in a big enough of a network we've got enough states that the company as long as it continues to replicate and scale and execute in the same way that it has been doing and that we have proven that we are able to do that growth from a Biotricity perspective between here and $50 million in revenue and even beyond that, we are on the same path as other players in the space that have been acquired, other players that are not in our industry in real-time cardiac diagnostics, but like passive diagnostics like iRhythm or companies that are in parallel industries like in sleep apnea or diabetes or what have you."
}